Australia's largest stock trading and investment forum Australia's #1 stock forum

RAC

3.79%

$1.53 race oncology ltd

Industry news, page-1886

First 1886 Last

Share
Profile

Follow
Bluegumnuts

7,025 Posts.

873

15/08/24

21:44

Post #: 75228692
Share

Originally posted by Davisite: ↑

If you want to play the game of resident downramper you need to make an effort and do some research first.

1. Those heart failure rates are based on old and crude measurements of the heart alone. New research looking at the effect of anathracyclines on the entire cardiovascular system has revealed that all patients suffer some level of permanent damage to their CV system. If you want references on this go and read the presentation from November 22 last year.

2. Dexrazoxane has been around for more than 30 years and it is basically not used. The reason why is it doesn’t offer any additional anticancer activity and potentially puts at risk the cancer treatment of the patient. This is where bisantrene is different in that it potentially offers both anticancer benefit plus cardioprotection. There is no need for any oncologist to put at risk the cancer treatment to protect the CV system of their patients.

3. The Triangle Research report did not say bisantrene would be used with every dose of doxorubicin. They were incredibly conservative in their market penetration estimation - when you actually calculate the peak uptake from their analysis it comes to a max of 3%.

Expand

just posted a very impressive Car T trail result with registrational trial attached…. Obviously it got a few upset which is why you responded.

a resident downramper hardly - but one who brings up
conversations which differ to the usual pump job here and I am sure new investors would find it interesting as your responses are quite educational….

Very cult like stock following in here which I guess keeps you at the top

RAC Price at posting: $1.57 Sentiment: None Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

What's causing the cost-of-living crisis, and how to navigate it

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%